Dissociation of CDK2 from cyclin A in response to the topoisomerase II inhibitor etoposide in v-src-transformed but not normal NIH 3t3 cells

Experimental Cell Research

Volumn 249, Issue 2, 1999, Pages 327-336

  Chen, Guan ^a   Hitomi, Masahiro ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

CDK2; Cyclin A dependent kinase; Etoposide; Oncogenic transformation; S phase arrest

Indexed keywords

CYCLIN A; CYCLIN DEPENDENT KINASE; ETOPOSIDE; GYRASE INHIBITOR;

ANIMAL CELL; ARTICLE; CELL CYCLE S PHASE; CELL STRAIN 3T3; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; MALIGNANT TRANSFORMATION; NONHUMAN; ONCOGENE SRC; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN PROTEIN INTERACTION;

ANIMALIA;

EID: 0033563637     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.1999.4484     Document Type: Article

References (56)

1. Sherr C. J. Cancer cell cycle. Science. 274:1996;1672-1677.
2. Hall M., Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res. 68:1996;67-108.
3. Sherr C. J., Roberts J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9:1995;1149-1163.
4. Peter M., Herskowitz I. Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell. 79:1994;181-184.
5. Bottazzi M., Assoian R. The extracellular matrix and mitogenic growth factors control G1 phase cyclins and cyclin-dependent kinase inhibitors. Trends Cell Biol. 7:1997;348-353.
6. Stacey D. W., Kung H. F. Transformation of NIH 3T3 cells by microinjection of Ha-ras p21 protein. Nature. 310:1984;508-511.
7. Dobrowolski S., Harter M., Stacey D. W. Cellular ras activity is required for passage through multiple points of the G0/G1 phase in BALB/c 3T3 cells. Mol. Cell. Biol. 10:1994;5314-5323.
8. Liu J., Chao J., Jiang M., Ng S., Yen J. J., Yan-Yen H. Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH 3T3 cells. Mol. Cell Biol. 15:1995;3654-3663.
9. kip1. Mol. Cell Biol. 17:1997;3850-3857.
10. Peeper D. S., Upton T. M., Ladha M. H., Neuman E., Zalvide J., Bernards R., DeCaprio J. A., Ewen M. E. Ras signaling linked to the cell-cycle machinery by the retinoblastoma protein. Nature. 386:1997;177-181.
11. Murnane J. Cell cycle regulation in response to DNA damage in mammalian cells: A historical perspective. Cancer Metas. Rev. 14:1995;17-29.
12. Kaufman W. K., Paules R. S. DNA damage and cell cycle checkpoints. FASEB J. 10:1996;238-247.
13. Weinert T. A. DNA damage checkpoint meets the cell cycle engine. Science. 277:1997;1450-1451.
14. Hartwell L. H., Kastan M. B. Cell cycle control and cancer. Science. 266:1994;1821-1828.
15. Elledge S. J. Cell cycle checkpoints: Preventing an identity crisis. Science. 274:1996;1664-1672.
16. Furnari B., Rhind N., Russell P. Cdc25 inducer targeted by Ch1 DNA damage checkpoint kinase. Science. 277:1997;1495-1497.
17. Sanchez Y., Wong C., Thoma R. S., Richman R., Wu Z., Piwnica-Worms H., Elledge S. J. Conservation of the Chk1 checkpoint pathway in mammals: Linkage of DNA damage to Cdk regulation through Cdc25. Science. 277:1997;1497-1501.
18. Peng C., Graves P. R., Thoma R. S., Wu Z., Shaw A. S., Piwnica-Worms H. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science. 277:1997;1501-1505.
19. Pardee A. B. A restriction point for control of normal animal cell proliferation. Proc. Natl. Acad. Sci. USA. 71:1974;1286-1290.
20. Fingert H. J., Campisi J., Pardee A. B. Cell proliferation and differentiation. Holland J., Frei E. III, Bast R., Kufe D. W., Morton D. L., Weichselbaum R. R. Cancer Medicine. 1993;1-32 Lea & Febiger, Philadelphia.
21. Belani C. P., Doyle L. A., Aisner J. Etoposide: Current status and future perspectives in the management of malignant neoplasms. Cancer Chemother. Pharmacol. 34:1994;S118-S126.
22. Nip J., Strom D., Fee B., Zambetti G., Cleveland J. L., Hiebert S. W. E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis. Mol. Cell Biol. 17:1997;1049-1056.
23. Chen G., Shu J., Stacey D. W. Oncogenic transformation potentiates apoptosis induction, S-phase arrest and WAF1 induction by etoposide. Oncogene. 15:1997;1643-1651.
24. Smith M. R., DeGudicibus S. J., Stacey D. W. Requirement for c-ras proteins during viral oncogene transformation. Nature. 320:1986;540-543.
25. Matsushime, H., Quelle, D., Shurtleff, S. A., Shibuya, M., Sherr, C., and Kata, J. Y.1994. D-type cyclin-dependent kinase activity in mammalian cells. Mol. Cell Biol.14, 2066-2076, 1994.
26. Hitomi M., Shu J., Strom D., Hiebert S. W., Harter M. L., Stacey D. W. Prostglandin A2 blocks the activation of G1 phase cyclin-dependent kinase without altering mitogen-activated protein kinase stimulation. J. Biol. Chem. 271:1996;9376-9383.
27. Kitagawa M., Higashi H., Jung H. K., Suzuki-Takahashi I., Ikeda M., Tamai K., Kato J., Segawa K., Yoshida E., Nishimura S., Taya Y. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO. J. 15:1996;7060-7069.
28. Logan T. J., Evans D. L., Mercer W. E., Bjornsti M. A., Hall D. J. Expression of a deletion mutant of the E2F1 transcription factor in fibroblasts lengthens S phase and increase sensitivity to S phase-specific toxins. Cancer Res. 55:1995;2883-2891.
29. Shan B., Lee W.-H. Deregulated expression of E2F-1 induces S- phase entry and leads to apoptosis. Mol. Cell. Biol. 14:1994;8166-8173.
30. Qin X. Q., Livingston D. M., Kaelin W. G. Jr., Adams P. D. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc. Natl. Acad. Sci. USA. 91:1994;10918-10922.
31. Kowalik T. F., DeGregori J., Schwarz J. K., Nevins J. R. E2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis. J. Virol. 69:1995;2491-2500.
32. DeGregori J., Leone G., Miron A., Jakoi L., Nevins J. Distinct roles for E2F proteins in cell growth control and apoptosis. Proc. Natl. Acad. Sci. USA. 94:1997;7245-7250.
33. Huang Y., Ishiko T., Nakada S., Utsugisawa T., Kato T., Yuan Z. M. Role for E2F in DNA damage-induced entry of cells into S phase. Cancer Res. 57:1997;3640-3643.
34. Girard F., Strausfeld U., Fernandez A., Lam N. J. C. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell. 67:1991;1169-1179.
35. Rosenberg A., Zindy F., Le Deist F., Mouly H., Metezeau P., Brechot C., Lamas E. Overexpression of human cyclin A advances entry into S phase. Oncogene. 10:1995;1501-1509.
36. Heichman K., Roberts J. M. Rules to replicate by. Cell. 79:1994;557-562.
37. Pines J. Cyclins and cyclin-dependent kinases: Theme and variation. Adv. Cancer Res. 66:1995;181-212.
38. Krude T., Jackman M., Pines J., Laskey R. A. Cyclin/Cdk-dependent initiation of DNA replication in a human cell-free system. Cell. 88:1997;109-119.
39. Krek W., Ewen M. E., Shirodkar S., Arany Z., Kaelin W. G., Livingston D. M. Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase. Cell. 78:1994;161-172.
40. Krek W., Xu G., Livingston D. M. Cyclin A-kinase regulation of E2F-1: DNA-binding function underlines suppression of an S phase checkpoint. Cell. 83:1995;1149-1158.
41. Trowbridge J. M., Rogatsky I., Garabedian M. J. Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex. Proc. Natl. Acad. Sci. USA. 94:1997;10132-10137.
42. Sheaff R. J. Regulation of mammalian cyclin-dependent kinase 2. Methods Enzymol. 283:1997;173-195.
43. Planas-Silva M., Weinberg R. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol. Cell Biol. 17:1997;4059-4069.
44. Poon R. Y. C., Toyoshima H., Hunter T. Redistribution of the CDK inhibitor p27 between different cyclin-CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation. Mol. Biol. Cell. 6:1995;1197-1213.
45. Reynisdottir I., Polyak K., Iavarone A., Massague J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β Genes Dev. 9:1995;1831-1845.
46. cdc2 kinase in etoposide-induced cell death of chinese hamster ovary cells. Cancer Res. 50:1990;3767-3771.
47. cdc2 kinase activity by etoposide or irradiation as a mechanism of G2 arrest in chinese hamster ovary cells. Cancer Res. 50:1990;3761-3766.
48. Waldman T., Lengauer C., Kinzler K. W., Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature. 381:1996;713-716.
49. Wang J. C. DNA topoisomerases. Annu. Rev. Biochem. 65:1996;635-692.
50. Chen A. Y., Liu L. F. DNA topoisomerases: Essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol. 34:1994;191-218.
51. Berger J. M., Gamblin S. C., Harrison S. C., Wang J. C. Structure and mechanism of DNA topoisomerase II. Nature. 379:1996;225-232.
52. Hsiang Y. H., Wu H. Y., Liu L. F. Proliferation-dependent regulation of DNA regulation of DNA topoisomerase II in cultured human cells. Cancer Res. 48:1988;3230-3235.
53. Nelson W. G., Cho K. R., Hsiang Y., Liu L. F., Coffey D. S. Growth-related elevations of DNA topoisomerase II levels found in dunning R3327 rat prostatic adenocarcinomas. Cancer Res. 47:1987;3246-3250.
54. Woessner R. D., Chung T. D. Y., Hofmann G. A., Mattern M. R., Mirabelli C. K., Drake F. H., Johnson R. K. Difference between normal and ras-transformed NIH-3T3 cells in expression of the 170KD and 180KD forms of topoisomerase II. Cancer Res. 50:1990;2901-2908.
55. Woessner R. D., Mattern M. R., Mirabelli C. K., Johnson R. K., Drake F. H. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ. 2:1991;209-214.
56. Wells N. J., Hickson I. D. Human topoisomerase IIα is phosphorylated in a cell-cycle phase-dependent manner by a proline-directed kinase. Eur. J. Biochem. 231:1995;491-497.